All In Biotech

Free tool

FAERS Monitor: Givlaari

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212194 or its brand name (Givlaari, Givosiran Sodium). Reports on generic versions are filed under their own applications.

Reports

1,559

Serious

1,173

75% of reports

Hospitalization

758

Death reported

51

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • porphyria acute495
  • hospitalisation182
  • intentional dose omission119
  • nausea118
  • product dose omission issue117
  • fatigue103
  • therapy interrupted103
  • pain92
  • malaise74
  • abdominal pain73
  • vomiting67
  • ill-defined disorder64
  • seizure64
  • inappropriate schedule of product administration51
  • unevaluable event49

Reports by year received

View as table
YearReports
202075
2021135
2022224
2023267
2024310
2025290
2026258

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,600 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
porphyria acuteSignal4957111.16454.62,300,634
intentional dose omissionSignal11956.547.66,419
therapy interruptedSignal10319.516.21,790
hospitalisationSignal18216.014.02,560
ill-defined disorderSignal6414.211.2775
unevaluable eventSignal498.76.6329
seizureSignal647.55.9355
product dose omission issueSignal1175.44.5417
abdominal painSignal734.23.4179
inappropriate schedule of product administrationSignal513.82.9104
malaiseSignal742.31.853
painSignal922.01.748
nauseaSignal1182.01.761
vomiting671.91.529
fatigue1031.81.536

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.